Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now

Since 1989, Windhover Information Inc. has been providing superior analysis and commentary on health care business strategy, industry dealmaking, marketplace trends, and the world of medical start-ups. The expertise that our editorial and research staff have developed--now consulted and relied upon by the industry's top executives, consultants, bankers and investors--finds voice in our publications, leading-edge conferences, and integrated, highly searchable databases of transactions and commentary. Windhover's editorial goal: to clearly present objective, accurate, fundamentally valuable decision-making information.

In March 2008, Windhover Information Inc. was acquired by Elsevier, the world’s leading publisher of science, technical and health information. In combining Windhover's analysis and commentary on business strategy, deal-making, and market trends, with the extensive and timely regulatory and reimbursement coverage of Elsevier's F-D-C Reports, we have built a comprehensive and interoperable source of information that biopharma and medical device professionals can rely upon to make critical business decisions.  Elsevier Business Intelligence is the name under which we will now be offering our full-line of products and services. For more information on this acquistion, view the press release here.

How we generate our content:

Windhover has amassed an unparalleled number of personal contacts at most companies in the pharmaceutical, biotech, medical device and diagnostic industries as well as in the investment banking, venture capital, consulting and other industry-support sectors. Our editorial and research staff leverages this extensive contact list in primary research, which we supplement with an extensive scanning, understanding and use of company and SEC documents. But whereas other information providers merely parrot back what they learn, Windhover's editors and writers use their extensive expertise in the industry to draw out the significance of the data, presenting not merely the facts but what we call the "so what" of trends, events, and strategies.

Related websites of interest:

Windhover Online (Subscribers) - sis.windhover.com
The RPM Report - www.rpmreport.com
Medtech Insight - www.medtechinsight.com
Company Profiles - companies.windhover.com
The IN VIVO Blog - invivoblog.blogspot.com
Elsevier - www.elsevier.com
FDC Reports - www.fdcreports.com


The IN VIVO Blog

IN3 Europe + Investor Day
April 28-30, 2010 · Paris, France

IN3 East + Investor Day
June 9-11, 2010 · Boston, MA

Euro-Biotech Forum
June 28-30, 2010 · Paris, France

Interested in presenting at a Windhover conference?
Submit your idea here


Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)

Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)

The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)

Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - About Us - Contact Us - Help - The IN VIVO Blog - RSS Feeds - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence